Abstract
Purpose: Since intravesically administered steroid therapy may treat bladder pain syndrome/interstitial cystitis (BPS/IC) with fewer side effects than the current treatment of orally administered steroids, we investigated whether the intravesical infusion of budesonide foam can effectively treat BPS/IC symptoms in a rat model of tranilast-induced BPS/IC. Methods: There were 6 rat treatment groups (n = 8 per group): control + single or daily saline infusion, tranilast + single or daily saline infusion, and tranilast + single or daily budesonide infusion. All groups except for the controls were fed a tranilast supplemented diet for 5 weeks. Budesonide and saline were infused intravesically. After the BPS/IC rat model underwent single infusion treatments, we measured the paw pain threshold using the von Frey test and continuous cystometry was taken. After two weeks of daily intravesical infusions, we measured locomotor activity and serum cortisol levels; harvested bladders underwent histological analysis. Results: Both pain threshold and locomotor activity were significantly lower in the saline-infused groups receiving the tranilast diet, but there were no differences between the budesonide-infused groups and the controls. The interval between bladder contractions was significantly shorter in the tranilast group than the control or tranilast + budesonide infusion groups. The serum cortisol levels did not change. Hematoxylin-Eosin stainings of the bladder showed thickening of the bladder muscle layer and mucosal edema in the tranilast group, while the tranilast + budesonide infusion group showed only mild changes. Conclusion: Intravesical infusion of budesonide effectively treated BPS/IC symptoms in a rat model of BPS/IC.
Highlights
Bladder pain syndrome/interstitial cystitis (BPS/IC) is defined as suprapubic pain associated with bladder filling in the absence of urinary tract infections or other diseases and is typically accompanied by increased daytime and nighttime urination frequency, according to both the European Society for the Study of Interstitial Cystitis (ESSIC) and the European Association of Urology (EAU) [1] [2]
Since intravesically administered steroid therapy may treat bladder pain syndrome/interstitial cystitis (BPS/IC) with fewer side effects than the current treatment of orally administered steroids, we investigated whether the intravesical infusion of budesonide foam can effectively treat BPS/IC symptoms in a rat model of tranilast-induced BPS/IC
Since intravesically administered steroid therapy may treat BPS/IC with fewer side effects than the current treatment of steroids administered orally, we investigated whether the intravesical infusion of budesonide foam can effectively control BPS/IC symptoms in a BPS/IC rat model induced by tranilast
Summary
Bladder pain syndrome/interstitial cystitis (BPS/IC) is defined as suprapubic pain associated with bladder filling in the absence of urinary tract infections or other diseases and is typically accompanied by increased daytime and nighttime urination frequency, according to both the European Society for the Study of Interstitial Cystitis (ESSIC) and the European Association of Urology (EAU) [1] [2]. When patients used tranilast to treat allergies, keloids, and hypertrophic scars, some of them sometimes developed BPS/IC [5] [6] [7]. We previously developed a BPS/IC rat model by administering high doses of tranilast to rats; our model closely resembles human BPS/IC because it has the typical signs and symptoms experienced by BPS/IC patients, such as increased urination frequency and decreased locomotor activity [10] [11]. Our BPS/IC rat model is characterized by having an extended bladder that leads to inflammation, increased vascular permeability, and the presence of glomerulations in the bladder wall [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
